Climb Bio, Inc. (CLYM) Analysis

By Exec Edge Editorial Staff Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes […]

Climb Bio is a biotech company. The story is incredibly simple, yet overlooked for a variety of technical (not fundamental) reasons. **What they do:** They have an anti-CD19 antibody, Budoprutug. It depletes B-cells. This is a very known mechanism of action, and fully de-risked. Anti-CD20 antibodies are some of the oldest (rituximab) drugs for autoimmune diseases. Targeting CD19 is slightly more broad and should provide better coverage and therefore potentially work better than CD20 antibodies...